In this study, we aimed to reveal the specific mechation. The stabilization of the agonistic conformation of nisms of TEI-9647 action by using these species-spethe VDR-LBD is achieved by the repositioning of its cific differences. We found that the bulky lactone ring most carboxy-terminal ␣ helix (helix 12). In detail, this is of this compound disturbs the exact positioning of helix 12 and therefore blocks the interaction with CoA pro- teins. Furthermore, in rat cells, we find that the residual
agonistic activity of TEI-9647 was higher than that obto that of solvent-treated cells. In contrast, at the same concentration (1 M), TEI-9647 showed significant reserved in human cells. We suggest that this is because the rodent-specific amino acids S403 and N410 display sidual agonistic activity (lanes 3, 9, 15, 21, and 27), which was higher in rat (41%-45% of 10 nM 1␣,25(OH) 2 D 3 ) than more and stronger interactions with TEI-9647 than C403 and C410 in humans. This results in a loss of the antagoin human (12%-15%) cells. The maximal induction of reporter gene activity through the natural agonist (lanes nist function of TEI-9647 in rodents.
1, 7, 13, 19, and 25) could be significantly reduced by a 100-fold molar excess of TEI-9647 in human cells Results and Discussion (34%-39%, lanes 11, 23, and 29) but not in rat cells (78%-81%, lanes 5 and 17). Remarkably, the five cell The functional profile of the VDR antagonists ZK168281 and TEI-9647 were compared in Ros17/2.8 (rat osteosarlines differ in their relative basal activity and therefore their maximal inducibility by 1␣,25(OH) 2 D 3 . For example, coma), MG-63 (human osteosarcoma), REK (rat epidermal keratinocytes), HaCaT (human immortalized kerain Ros17/2.8 cells (lane 6) the basal activity was more than two times higher than in MCF-7 cells (lane 30). tinocytes), and MCF-7 (human breast cancer) cells. For this purpose, native VDR activity was assayed in the Taken together, the data indicate that TEI-9647 is a partial antagonist only in human cellular models but not presence of the appropriate ligand using a luciferase reporter gene construct driven by four copies of a direct in rat cells. In contrast, ZK168281 is a pure antagonist in both species. repeat (DR)3-type VDRE derived from the rat atrial natriuretic factor (ANF) gene. This construct was transiently
The observation of the species-specific difference in the functional profile of TEI-9647 led us to hypothesize transfected into the five cell lines, and the relative luciferase activity was determined after overnight stimulation that it may be caused by amino acid differences in the VDR of rodent and human. The amino acid sequences in the presence of the appropriate ligand (Figure 1) . In all cellular systems, ZK168281 was shown to have of whole mouse and rat VDR are 96% identical, whereas the identities of both rodent VDRs with human VDR is insignificant agonistic activity (lanes 2, 8, 14, 20, and 26). In combination with the natural agonist (lanes 4, 88%. However, only two amino acids differ between human and rodent VDR in the region close to the ligand 10, 16, 22, and 28), this ligand suppresses the natural ligand's inductive effect to a level which is comparable binding pocket and helix 12. These differences occur by adding 10 l protein gel loading buffer (0.25 M Tris [pH 6.8], were subcloned into the SV40 promoter-driven pSG5 expression 20% glycerol, 5% mercaptoethanol, 2% SDS, 0.025% bromophenol vector (Stratagene, La Jolla, CA). The same constructs were used blue). The samples were denatured at 85ЊC for 3 min and electrophofor both T 7 RNA polymerase-driven in vitro transcription/translation resed through 15% SDS-polyacrylamide gels. The gels were dried, of the respective cDNAs and for viral promoter-driven overexpresexposed to a Fuji MP2040S imager screen, and monitored on a Fuji sion of the respective proteins in mammalian cells. The point mu-FLA3000 reader. tants of VDR were generated using the QuikChange Point Mutagenesis Kit (Stratagene) and confirmed by sequencing. The luciferase MD Simulations reporter gene was driven by four copies of the rat ANF DR3-type
The initial coordinates for the MD simulations were obtained from binding site (core sequence AGAGGTCATGAAGGACA) fused to the the X-ray crystal structure of the VDR LBD-1␣,25(OH) 2 D 3 complex tk promoter. The NR interaction domain of human TIF2 (spanning (Protein Data Bank code 1DB1) determined to 1.8 Å resolution [7] . amino acids 646 to 926) [28] was subcloned into the GST fusion
The missing amino acid residues of the X-ray structure (residues vector pGEX (Amersham-Pharmacia, Uppsala, Sweden).
118, 119, 375-377, and 424-427) were built using the Quanta98 molecular modeling package (Molecular Simulations Inc., San Diego, CA). The four residues missing from the C terminus (424-427) Transfection and Luciferase Reporter Gene Assays Ros17/2.8 (rat osteosarcoma), MG-63 (human osteosarcoma), REK were built in an ␣-helical conformation (φ ϭ Ϫ57Њ, ϭ Ϫ47Њ). The two VDR antagonists, ZK168281 and TEI-9647, were docked to the (rat epidermal keratinocytes), HaCaT (human immortalized keratinocytes), and MCF-7 (human breast cancer) cells were seeded into ligand binding site of LBD using the locally enhanced sampling
